Drugs / Tonlamarsen
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04731623 | Feb → Aug 2021 | — | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07511361 | Jun → Dec 2026 expected | hypertensive urgency | Kardigan, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06864104 | Apr 2025 → Jan 2026 | hypertensive disorder | Kardigan, Inc. | Completed | Mixed |
| Phase 2 | NCT05314439 | Apr 2022 → Jan 2023 | hypertensive disorder | Ionis Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-28 | Kardigan, Inc. | Results Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC kardigan.bio ↗
In the clinical trial, tonlamarsen, an investigational antisense oligonucleotide (ASO) targeting angiotensinogen (AGT), demonstrated a statistically significant reduction in plasma AGT levels and a clinically meaningful reduction in in-office systolic blood pressure (oSBP) from baseline to Week 20. |
All press releases naming this drug 1 release
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tonlamarsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07511361 ↗ |
| Known as | ION-904 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095350 ↗ |
| Known as | ION904 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05314439 ↗ |
| Action | Inhibit | “directed against hepatic angiotensinogen synthesis” PMID 41949512 ↗ Mar 2026 |
| Modality | Antisense oligonucleotide | “Tonlamarsen is an investigational antisense oligonucleotide directed against hepatic angiotensinogen synthesis” PMID 41949512 ↗ Mar 2026 |
| Route | Subcutaneous | “ION904 will be administered by SC injection.” NCT04731623 ↗ |
| Target | AGT | “Tonlamarsen is designed to block the body's liver from making a protein called angiotensinogen (AGT), which plays a key role in controlling blood pressure.” NCT07511361 ↗ |